ENABLEX (Darifenacin) is an M3 selective receptor antagonist (M3 SRA), which works by selectively blocking a receptor involved in the control of bladder muscle contraction. ENABLEX, a new oral treatment for overactive bladder (OAB), has the potential to prolong warning time the period between the first sensation of urgency and urination in patients experiencing OAB syndrome.

ENABLEX decreases the severity and frequency of urges, allowing patient to go to the bathroom fewer times per day. ENABLEX helps patients bladder hold more urine before you feel the need to urinate. ENABLEX may begin to relieve symptoms in as little as 2 weeks.